BRAF and melanoma: Signalling requiring the PI3K pathway and the activation of the PI3K pathway itself have both also been implicated in the development of melanoma’s resistance to BRAF/MEK inhibitors [13, 14, 17, 18] and immune checkpoint inhibitors [19, 20].